Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- NEW PRODUCTS
July 29, 2002
- Tanabe Aims at World-class Performance for Each Division: President Hayama
July 29, 2002
- FY2003 Budget Formation Schedule Confirmed
July 29, 2002
- US Consumers Appreciate Online Healthcare Information: PhRMA Seminar
July 29, 2002
- REGULATORY NEWS IN BRIEF
July 29, 2002
- 15th Interphex Japan
July 29, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
July 29, 2002
- Nippon Chemiphar to Beef Up Its Generic Business
July 29, 2002
- Asahi Kasei to Look For Lead Compounds with SGX
July 29, 2002
- Promoting GE Use Needs Various Means: Mr Wright of EFPIA
July 29, 2002
- MPC-backed New Foundation Invites Applications for CV Research Grants
July 29, 2002
- Takeda to Expand Lineup of Antidiabetic Drugs
July 29, 2002
- Kuraya Sanseido Acquires ATOL's Business in Tokyo, Kanagawa
July 22, 2002
- Sankyo Pharma to Market Cygnus' GlucoWatch
July 22, 2002
- MOSS Institute to Be Listed on August 8
July 22, 2002
- Shionogi-GSK Announces 1st Clinical Trial Results for New Anti-HIV Drug
July 22, 2002
- Number of Wholesalers to Decrease to 3 to 40 by 2011: YRI Report
July 22, 2002
- First Study on Palliative Medicine in Japan Completed
July 22, 2002
- Monkasho Holds Symposium on National Bioresources Project
July 22, 2002
- WORLD NEWS IN BRIEF
July 22, 2002
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…